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a b s t r a c t
Background: Protocols on the use of novel oral anticoagulants for stroke prevention in patients with
atrial ﬁbrillation (AF) undergoing electrical cardioversion (ECV) are lacking.
Aim: The study was aimed at evaluating the efﬁcacy of dabigatran (Dabi) treatment in preventing peri-ECV
stroke.
Methods: A retrospective survey of the incidence and fate of left atrial (LA) thrombus during Dabi therapy in
patients with AF was conducted between December 2012 and January 2013 by the Japanese Heart Rhythm
Society.
Results: A total of 198 patients from 299 institutions underwent transesophageal echocardiography (TEE) to
rule out LA thrombus before ECV. Of these, LA thrombus was found in eight patients (4%), who tended to be
older (67.3 vs. 61.3 years, p¼0.175), had higher CHADS2 scores (1.88 vs. 0.95, p¼0.058), and a higher prevalence
of prior stroke or transient ischemic attack (22.2% vs. 2.6%, p¼0.034) than those without LA thrombus. Of the
eight patients with LA thrombus, one had LA thrombus during a Dabi 150 mg b.i.d treatment, whereas the
remaining seven were receiving 110mg b.i.d for 3 weeks or longer. In 6 of the 8 patients with LA thrombus, a
second TEE was performed, revealing complete resolution of LA thrombus in ﬁve; among these ﬁve patients,
one received Dabi dosage of 150mg b.i.d unchanged, two received an increased dosage from 110mg to 150mg
b.i.d, and two were switched to warfarin. Two patients had a stroke 3 and 15 days after ECV, and one had a
major large intestine bleeding episode during Dabi therapy.
Conclusions: LA thrombus developed in 4% of patients with AF receiving Dabi. Older patients with a higher
CHADS2 score receiving a lower Dabi dosage were more likely to develop LA thrombus, which was resolved
with a prolonged or increased dosage. A higher Dabi dosagemay bemore beneﬁcial before ECV but prospective
randomized studies would be needed to conﬁrm these results.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Stroke prevention is of prime importance in the management of
patients with atrial ﬁbrillation (AF). Although the risk of thromboem-
bolic stroke is predicted by a variety of factors, including those
indicated by the CHADS2 score, electrical cardioversion (ECV) is a
special situation where this risk increases temporarily.
Warfarin administration is recommended for at least 3 weeks
and 4 weeks before and after elective ECV, respectively, unless the
possibility of left atrial (LA) thrombus is excluded by transesopha-
geal echocardiography (TEE) [1–4]. However, the validity of this
approach for the use of novel oral anticoagulants (NOACs) is
unknown.
Since dabigatran (Dabi) was ﬁrst introduced in clinical practice
on March 14, 2011 in Japan, ECV has been performed during Dabi
therapy, providing an opportunity to examine both LA thrombus
formation and resolution in patients with AF. Accordingly, the
Japanese Heart Rhythm Society (JHRS) conducted a survey of the
incidence and the fate of LA thrombus.
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2. Materials and methods
A retrospective questionnaire survey was conducted among 299
JHRS institutions from December 2012 to January 2013. Patients with
persistent AF who underwent TEE for elective ECV were included. LA
thrombus incidence, risk factors for thrombus formation as indicated
by the CHADS2 score, history of gastrointestinal bleeding, Dabi dosage
(110 mg b.i.d or 150 mg b.i.d), treatment duration before ECV (o3
weeks, 3–6 weeks, Z6 weeks) and after ECV (o4 weeks, Z4 weeks),
and co-administration of amiodarone or verapamil were examined.
Patients with LA thrombus underwent repeated TEE to determine LA
thrombus fate and the possibility of thrombus resolution. Further-
more, embolic as well as hemorrhagic complications occurring in
patients without LA thrombus were evaluated within 1 month of ECV
while on Dabi.
Comparisons between patients with and without LA thrombus
were made using a Student t-test for age and a chi-square test for
other variables.
3. Results
3.1. LA thrombus prevalence
A total of 198 patients underwent TEE to rule out the presence of
LA thrombus before ECV. The average age was 61.6 years with an 84%
male predominance. The average CHADS2 score was 0.99 with 3.5% of
patients having a history of stroke or transient ischemic attack.
Dabi 150 mg b.i.d and 110 mg b.i.d were given to 98 and 100
patients, respectively. LA thrombus was found in one patient
receiving the higher dosage while seven patients received the
lower dosage (p¼0.076) (Table 1). The decision to administer the
lower dosage in 58% of patients was based on Japan's recommen-
dations, which requires the fulﬁllment of one of the following
criteria: creatinine clearance rate, 30–50 mL/min; co-adminis-
tration of p-glycoprotein inhibitors such as amiodarone or ver-
apamil; age Z70 years; or a history of gastrointestinal bleeding. In
the remaining 42% of patients, physicians arbitrarily selected the
lower dosage.
Dabi was administered for o3 weeks in 21%, for 3–6 weeks in
24%, and for Z6 weeks in 55% of patients prior to TEE.
3.2. Characteristics of LA thrombus patients
LA thrombus was found in eight (4%) out of 198 patients (Fig. 1).
The eight patients with LA thrombus tended to be older (67.3 vs. 61.3
years, p¼0.175), had higher CHADS2 scores (1.88 vs. 0.95, p¼0.058),
and had a higher prevalence of prior stroke or transient ischemic
attack (22.2% vs. 2.6%, p¼0.034) than those without LA thrombus
(Table 1).
Of the eight patients with LA thrombus, one was receiving a
Dabi dosage of 150 mg b.i.d, whereas the remaining seven were
receiving 110 mg b.i.d for Z3 weeks. Notably, in three of these
seven patients, the dosage of 110 mg b.i.d was arbitrarily selected
and did not reﬂect the Japanese recommendations for dosage
reduction as described in Section 3.1.
3.3. LA thrombus fate
A second TEE was performed in six of the eight patients with LA
thrombus, which revealed complete resolution of the thrombus in
ﬁve patients with the earliest resolution within 23 days after the ﬁrst
TEE (Fig. 1). Of these ﬁve patients, one was receiving a prolonged
Dabi dosage of 150 mg b.i.d, two had an increase in dosage from
110 mg to 150 mg b.i.d, and the remaining two were switched to
warfarin (Table 2, Figs. 2 and 3). One patient undergoing the second
Table 1
Characteristics of patients with and without left atrial thrombus. TIA, transient
ischemic attack.
LA thrombus
()
LA thrombus
(þ)
Total p Value
n 190 8 198
Age (yrs;
mean7SD)
61.3712.0 67.3712.7 61.6712.1 p¼0.175
Male (n) 160 7 167
CHADS2 score
(mean)
0.95 1.88 0.99 p¼0.058
0 or 1 (n) 141 3 144
2 (n) 29 4 33
3–6 (n) 14 1 15
Unknown (n) 6 0 6
Prior stroke/TIA (n) 5 2 7 p¼0.034
150 mg b.i.d 97 1 98
p¼0.076
110 mg b.i.d 93 7 100
As recommendedn 54 4 58
n Dose reduction to 110 mg b.i.d according to Japan's recommendations
described in the text.
Pre -ECV TEE
N = 198
LA thrombus (+)
N = 8 (4%)
2nd TEE
N = 6
LA thrombus resolution
N = 5
LA thrombus shrinkage
N = 1
Fig. 1. Summary of serial TEE ﬁndings. ECV, electrical cardioversion; TEE, transe-
sophageal echocardiography; LA, left atrial.
Table 2
Characteristics of the eight patients with left atrial thrombus. No, number; Wt, weight; CLcr, creatinine clearance; Dabi, dabigatran; Wks, weeks; TEE, transesophageal
echocardiography; OAC, oral anticoagulants.
Patient
no.
Age Sex Wt
(kg)
CLcr
(mL/m)
CHADS2
score
Dabi dosage
(mg, b.i.d)
Wks of Dabi prior to 1st
TEE
2nd OAC for LA
thrombus
Days to 2nd
TEE
Fate of LA
thrombus
1 82 M 68 64 4 110n 3–6 110 – Unknown
2 63 M 83 77 2 110 ≧6 Warfarin 23 Disappeared
3 70 M 52 55 2 110n ≧6 150 58 Disappeared
4 78 M 90 66 2 110n ≧6 Warfarin – Unknown
5 82 M 41 42 2 110n ≧6 Warfarin 9 Shrank
6 49 M 96 154 1 110 ≧6 150 121 Disappeared
7 58 M 61 89 1 150 ≧6 150 308 Disappeared
8 56 F 81 100 1 110 ≧6 Warfarin 49 Disappeared
n Dose reduction to 110 mg b.i.d according to Japan's recommendations described in the text.
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TEE 9 days after warfarin therapy only showed LA thrombus
shrinkage.
3.4. ECV complications
ECV was carried out in both 190 patients without LA thrombus
and in ﬁve patients after LA thrombus resolution. ECV was not
attempted in the three remaining patients with no LA thrombus
resolution conﬁrmation by TEE. Two patients (1%) had a stroke at
days 3 and 15 after ECV while on Dabi 110 mg b.i.d, although LA
thrombus was not detected before ECV. The former patient had
CHADS2 score zero, but received a lower dosage of 110 mg b.i.d
arbitrarily selected by a physician, and the latter was an 83-year-
old patient with hypertension. A 68-year-old male diabetic patient
receiving a Dabi dosage of 110 mg b.i.d had a major large intestine
bleeding episode secondary to colon carcinoma and required
hospitalization.
4. Discussion
4.1. Main ﬁndings
LA thrombus developed in 4% of patients with AF despite Dabi
administration before elective ECV, as shown on TEE. Older
patients with higher CHADS2 score, an inappropriately Dabi lower
dosage, or a shorter treatment duration appeared to be more
susceptible to LA thrombus formation. LA thrombus resolution was
achieved typically after an increase in Dabi dosage or switching to
warfarin. Finally, although peri-ECV thromboembolic complica-
tions were rare, they occurred despite the previous absence of LA
thrombus.
LA thrombus formation in AF patients receiving NOAC treat-
ment has not been studied extensively. Although modalities to
examine LA thrombus such as computed tomography or intracar-
diac echocardiography exist, TEE is by far the most popular and
reliable method being used in clinical practice [3,4]. However,
because of its invasive nature, TEE is indicated only in patients
undergoing ECV or AF ablation to exclude the presence of LA
thrombus before the procedure. This survey has thus provided an
opportunity to ascertain LA thrombus prevalence among patients
with persistent AF selected to undergo elective ECV.
4.2. LA thrombus development during warfarin therapy
This survey demonstrated the presence of LA thrombus in 4% of
patients with AF despite all receiving anticoagulant therapy with
Dabi for at least 3 weeks. Although it may not be appropriate to
compare this result with those of previous studies using warfarin, a
single-center study in Germany including 799 patients with persis-
tent AF receiving warfarin for at least 3 weeks and with a pro-
thrombin time–international normalized ratio (PT–INR) between
2 and 3 detected LA thrombus using TEE in 7.7% [5]. In that study,
thromboembolic events developed within 4 weeks of ECV at a rate of
0.8% in both groups of patients receiving the TEE guided and non-
guided conventional approach, indicating that LA thrombus, even if
present, may not necessarily be dislodged to cause thromboembolic
events occurring after ECV. Although the prevalence of LA thrombus
has been variable depending on the subjects studied, it was 4% if TEE
was performed within 48 h of AF without prior anticoagulation [6].
ECV without oral anticoagulant therapy was previously accepted
in patients with o48 h of AF [7]. However, a recent Finnish study
demonstrated that even in this set of patients, the risk of throm-
boembolic events can reach up to 9.8% among those with both heart
failure and diabetes [8]. On the other hand, LA thrombus prevalence
was reported to be 3% in the above-mentioned German study when
TEE was performed in 295 low-risk patients with AF with a CHADS2
score of 0 or 1 [9]. LA thrombus prevalence or sludge increases with
increasing scores of CHADS2 and CHA2DS2-VASc [10,11]. Therefore, it
was not surprising that in our survey, patients with LA thrombus
tended to be older and had a higher CHADS2 score and prevalence of
previous stroke or transient ischemic attack than those without
demonstrable LA thrombus.
4.3. LA thrombus development during NOAC use
Although Dabi appears to be an effective alternative to warfarin
in preventing stroke or systemic embolism without requiring
PT–INR monitoring, the fact that 4% of patients receiving Dabi still
had LA thrombus in our survey suggests that TEE is useful when
performed before elective ECV of persistent AF. Thrombus may
Fig. 2. Fate of left atrial thrombus in the eight patients. TEE, transesophageal
echocardiography.
2ndTEE on 150 mg b.i.d for 4 months1stTEE on 110 mg b.i.d
Fig. 3. Left atrial (LA) thrombus resolution demonstrated on serial TEE in one patient. A small thrombus is shown in the LA appendage during Dabi treatment with 110 mg
bid (left).
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develop even under Dabi treatment in the presence of mechanical
heart valves or rheumatic mitral stenosis [12,13], but a few cases of
failure to prevent LA thrombus formation with the use of this
agent have also been reported in patients with AF without such
backgrounds [14–16]. Although it is hard to prove, we speculate
that not only higher CHADS2 scores, but also the insufﬁcient Dabi
dosage given to some of our patients might have led to inadequate
anticoagulation and subsequent clot formation. Three of the seven
patients taking this lower dosage did not fulﬁll any of the
recommendation criteria for using a 110 mg b.i.d dosage, but
whether a 150 mg b.i.d dosage could have prevented LA thrombus
formation in these patients remains uncertain.
In the RE-LY study, where TEE was performed according to
physicians' preference, LA thrombus was detected in 1.8% of 165
patients and in 1.2% of 162 patients receiving 110 mg b.i.d and
150 mg b.i.d dosage, respectively [17]. Although the results of the
RE-LY study were in line with ours, we observed a higher incidence
of LA thrombus at the lower Dabi dosage, which could be a reﬂection
of shorter anticoagulation duration as well as a potentially lower
patient adherence to Dabi treatment, in a real-world scenario. Dabi
treatment adherence was not carefully evaluated in this survey, but
poor adherence in some patients could have been responsible for
inadequate anticoagulation. As LA thrombus can develop in a
substantial number of patients receiving Dabi, we recommend TEE
for every ECV candidate, but whether this also applies to other
NOACs remains uncertain. Peri-ECV complication sub-analysis in
prospective studies yielded variable stroke or systemic embolism
rates of 0.8% and 0.3% at Dabi dosages of 110 mg and 150 mg b.i.d in
the RE-LY study, respectively, 1.8% with rivaroxaban in the ROCKET
AF study, and 0% with apixaban in the ARISTOTLE study 30 days
after ECV [18,19]. A recent prospective randomized trial comparing
rivaroxaban and vitamin K antagonists for AF cardioversion failed to
show any signiﬁcant difference in the primary efﬁcacy and safety
outcomes [20]. However, in a small patient subgroup where TEE was
performed optionally, LA thrombus was found in six out of 33
patients versus zero out of 31 patients receiving rivaroxaban or
vitamin K antagonists, respectively, for 3–8 weeks prior to ECV.
4.4. Stroke after negative TEE
In our study, two patients (1%) had a stroke after ECV. Although
not every preexisting LA thrombus might cause thromboembolism
after ECV, stroke incidence could have been higher if ECV had been
performed without prior TEE. However, it is noteworthy that TEE
was not able to detect LA thrombus in any of these two patients
before ECV. Thromboembolic events after a negative TEE are
common and have signiﬁcant clinical importance. One possibility
is that TEE has limited power to detect a preexisting small LA
thrombus or sludge. Although dense spontaneous echo contrast
was not systematically evaluated in this survey, sludge is not only
considered to be a precursor, but may also mask the detection of a
well-formed LA thrombus. Baseline myocardial structure such as
the pectinate muscles of the LA appendage may also be sometimes
erroneously diagnosed as LA thrombus, while the contrary can
lead to its underdiagnosis. However, as the CHADS2 score was zero
in one of these two patients, a more plausible explanation would
be de novo LA thrombus formation as a consequence of ECV itself.
Atrial function is known to remain reduced for Z3 weeks after
ECV, and this may provide a milieu for de novo thrombus for-
mation [21]. Based on repeated TEE in ﬁve patients with stroke
after negative TEE, Black et al. found new or increased LA spo-
ntaneous echo contrast in four patients including one patient with
a new LA appendage thrombus [22]. When TEE was carried out
within 5–15 min of ECV, Grimm et al. found spontaneous echo
contrast developing de novo in 4 of the 20 patients [23]. Further-
more, Fatkin et al. carried out ECV in 15 patients while TEE was in
place and found that within 10 s of successful ECV, LA spontaneous
echo contrast appeared in ﬁve and increased in one, which was
associated with a transient atrial dysfunction (stunning) [24]. LA
thrombus formation immediately after ECV has also been demon-
strated on TEE or intracardiac echo during AF ablation [25,26].
Therefore, the possibility of ECV causing or unmasking atrial
stunning and potentially inactivating thrombogenic factors in the
atrial endocardium or blood constituents should not be under-
estimated. More importantly, the limited power of TEE in predict-
ing later LA thrombus formation should be kept in mind.
4.5. LA thrombus resolution with NOAC use
LA thrombus resolution is another important observation in this
survey. Of the six patients in whom LA thrombus was detected in
the ﬁrst TEE and later underwent a second TEE, ﬁve experienced
thrombus disappearance Z3 weeks later, and one showed throm-
bus shrinkage after 9 days of anticoagulant therapy. Although
prolonged treatment with Dabi 150 mg b.i.d and increasing the
dosage up to 150 mg b.i.d or switching to warfarin appeared to be
effective in thrombus resolution in three and two patients, respec-
tively, the number of patients was too small and the protocol was
not standardized or randomized to be able to reach a deﬁnite cause-
effect relationship regarding this observation. Stoddard et al. found
that of 21 patients undergoing serial TEE, LA thrombus resolved
only in one patient at 3–5 weeks of warfarin therapy, and in the
8 additional patients at 5–17 weeks [27]. An ACUTE study sub-
analysis revealed complete thrombus resolution in 26 (76.5%) of 34
patients undergoing a repeat TEE after an average of 31.7 days of
warfarin anticoagulation therapy [28]. Therefore, LA thrombus
resolution is a common phenomenon that can result from either
active or passive effects of any anticoagulant.
The potential thrombolytic effect of Dabi has been previously
described [29–31]. Warfarin anticoagulation effects may not only
be difﬁcult to control at times, but could also exert a transient
thrombogenic action in its loading phase [32]. By contrast, Dabi
may create a consistent anticoagulation milieu easier and faster
while inhibiting thrombin binding to ﬁbrin and ﬁbrin degradation
products [33,34]. LA thrombus resolution has also been reported
with rivaroxaban and apixaban [35–38]. However, additional
prospective and detailed studies are necessary before Dabi or
any NOAC is recommended for clot resolution.
4.6. Study limitations
There are several limitations in this study. This retrospective study
was carried out without following a consistent protocol for Dabi
dosage and therapy duration prior to or after ECV. The possibility of
selection bias cannot be excluded as a TEE was performed at the
discretion of individual doctors. No protocol was provided for dosage
change or type of oral anticoagulants, or for the timing of the second
TEE after LA thrombus detection, nor was an assessment available to
ascertain Dabi adherence before and after ECV. Individual doctors
with potentially variable skills made LA thrombus diagnosis by
using TEE.
5. Conclusions
LA thrombus developed in 4% of patients with AF who under-
went ECV while receiving Dabi. Older patients with higher CHADS2
score who were receiving a lower Dabi dosage or shorter treatment
duration were more likely to develop LA thrombus, which resolved
with a prolonged or increased dosage. A higher Dabi dosage may be
preferred to a lower dosage if acceptable before ECV, but further
prospective randomized studies are needed to conﬁrm these
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ﬁndings. Considering the limitation of ascertaining Dabi therapy
adherence, performing a TEE in all patients receiving Dabi before
ECV may be recommended.
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Appendix A
A.1 List of the institutions participating in the survey
Teine Keijinkai Hospital, Hokkaido University Hospital, National
Hospital Organization Obihiro National Hospital, Akita Medical
Center, Hiraka General Hospital, Iwate Medical University Hospital,
Sendai City Hospital, University of Fukui Hospital, Fukui-ken Saiseikai
Hospital, Ishikawa Prefectural Central Hospital, Nihon University
Hospital, St. Luke's International Hospital, Jikei University School of
Medicine, Toranomon Hospital, The Cardiovascular Institute, Tokyo
Metropolitan Hiroo Hospital, Kawasaki Municipal Tama Hospital,
Yokohama City Minato Red Cross Hospital, Yamatoseiwa Hospital,
Shonan Kamakura General Hospital, Fukuyama City Hospital, New
Tokyo Hospital, Juntendo University Urayasu Hospital, Kameda Gen-
eral Hospital, Dokkyo Medical University Hospital, Saitama Interna-
tional Medical Center, Gunma University Hospital, Seirei Hamamatsu
General Hospital, Hamamatsu Medical Center, Okazaki City Hospital,
Japan Community Healthcare Organization Chukyo Hospital, Japa-
nese Red Cross Nagoya Daini Hospital, Konan Kosei Hospital, Gifu
Heart Center, Gifu University Hospital, Gifu Prefectural Tajimi Hospi-
tal, Mie University Hospital, Shiga University of Medical Science
Hospital, Hikone Municipal Hospital, Sakurabashi Watanabe Hospital,
Osaka Police Hospital, Osaka City University Hospital, Tominaga
Hospital, Osaka General Medical Center, National Cerebral and
Cardiovascular Center, Ishikiriseikikai Hospital, Kyoto Prefectural
Medical University Hospital, National Hospital Organization Kyoto
Medical Center, Nara Medical University Hospital, Nara Prefecture
Western Medical Center, Kobe University Hospital, Hyogo College of
Medicine Hospital, Hyogo Brain and Heart Center, Tottori Prefecture
Chuo Hospital, Matsue Red Cross Hospital, Sakakibara Heart Institute
of Okayama, Aichi Medical University Hospital, Kurashiki Central
Hospital, Fukuyama Cardiovascular Hospital, Okayama University
Hospital, Hiroshima Prefectural Hospital, Tokushima Red Cross
Hospital, Ehime University Hospital, Kyushu Hospital, National Hos-
pital Organization Kyushu Medical Center, Kyushu University Hospi-
tal, Fukuoka Sanno Hospital, Fukuoka University Hospital, Saga-ken
Medical Centre Koseikan, National Hospital Organization Oita Med-
ical Center, and Tomishiro Chuo Hospital.
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